Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Retrieved on:
월요일, 9월 26, 2022
SBRT, Therapy, Health, Safety, COVID-19, Otorhinolaryngology, Mucositis, Peripheral, NSCLC, GC4419, LAPC, Privacy, Early Stage, Annual general meeting, Pancreatic cancer, Society, Chemoradiotherapy, American Society for Radiation Oncology, Neoplasm, Cancer, Ownership, 2021 Essex County Council election, CDT, Annual report, Nasdaq, Private Securities Litigation Reform Act, ASTRO, AESOP, Radiation therapy, Large-cell lung carcinoma, SOM, GLOBE, SEC, Failure, Central neurogenic hyperventilation, Pharmaceutical industry, Patient
Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
Key Points:
- Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
- Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer.
- Galeras selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities.
- This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.